This technology is a PEG-fluoxetine conjugate designed for oral delivery that enables localized intestinal drug activity for the treatment of inflammatory bowel disease.
Inflammatory bowel disease (IBD) is a lifelong chronic inflammatory disorder of the gastrointestinal (GI) tract without an effective cure. Current treatments of IBD aim to alleviate the symptoms, in which selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (FLX), have demonstrated anti-inflammatory effects in preclinical models of IBD. However, orally administered FLX is rapidly absorbed into the bloodstream, limiting drug exposure in the GI tract. This compromises its therapeutic effect against IBD and raises concerns over systemic side effects in long-term use.
This technology is a multi-arm polyethylene glycol-fluoxetine (PEG-FLX) conjugate designed for oral delivery to enable localized therapeutic action against inflammatory bowel disease (IBD). The PEG-FLX conjugate reduces serotonin uptake in intestinal cells to achieve an anti-inflammatory effect and exhibits prolonged GI retention due to its multi-arm PEG structure. By maintaining higher levels of FLX in the intestine, this conjugate has demonstrated therapeutic efficacy and alleviation of IBD symptoms in vivo.
This technology has been validated in vitro in human intestinal cells and in vivo in an IBD mouse model.
Patent Pending
IR CU25441
Licensing Contact: Dovina Qu
